{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:34:35Z","timestamp":1793406875788,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s40265-014-0298-1","type":"journal-article","created":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T04:44:33Z","timestamp":1412138673000},"page":"1769-1784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"74","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,2]]},"reference":[{"issue":"Suppl 1","key":"298_CR1","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2337\/dc12-s064","volume":"35","author":"American Diabetes Association","year":"2012","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64\u201371.","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"298_CR2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association. Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36(Suppl 1):S11\u201366.","journal-title":"Diabetes Care."},{"key":"298_CR3","unstructured":"International Diabetes Federation. Diabetes: facts and figures.\u00a02013. http:\/\/www.idf.org\/worlddiabetesday\/toolkit\/gp\/facts-figures . Accessed 22 Aug 2014."},{"key":"298_CR4","unstructured":"International Diabetes Federation. Global diabetes plan 2011-2021. 2011. http:\/\/www.idf.org\/sites\/default\/files\/Global_Diabetes_Plan_Final.pdf . Accessed 30 May 2014."},{"key":"298_CR5","unstructured":"International Diabetes Federation. Morbidity and mortality. 2009. http:\/\/www.idf.org\/diabetesatlas\/diabetes-mortality . Accessed 22 Aug 2014."},{"issue":"6","key":"298_CR6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statment of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364\u201379.","journal-title":"Diabetes Care."},{"issue":"2","key":"298_CR7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tips.2010.11.011","volume":"32","author":"CJ Bailey","year":"2011","unstructured":"Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32(2):63\u201371.","journal-title":"Trends Pharmacol Sci."},{"issue":"1","key":"298_CR8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2337\/diaspect.25.1.29","volume":"25","author":"B Dokken","year":"2012","unstructured":"Dokken B. The kidney as a treatment target for type 2 diabetes. Diabetes Spectr. 2012;25(1):29\u201336.","journal-title":"Diabetes Spectr."},{"issue":"1","key":"298_CR9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83\u201390.","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"298_CR10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.16","volume":"2","author":"L Seman","year":"2013","unstructured":"Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(2):152\u201361.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"3","key":"298_CR11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2133\/dmpk.DMPK-12-RG-082","volume":"28","author":"A Sarashina","year":"2013","unstructured":"Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28(3):213\u20139.","journal-title":"Drug Metab Pharmacokinet."},{"issue":"7","key":"298_CR12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","volume":"15","author":"T Heise","year":"2013","unstructured":"Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4\u00a0weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613\u201321.","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"298_CR13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","volume":"4","author":"T Heise","year":"2013","unstructured":"Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013;4(2):331\u201345.","journal-title":"Diabetes Ther."},{"issue":"6","key":"298_CR14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/jdi.12110","volume":"4","author":"S Kanada","year":"2013","unstructured":"Kanada S, Koiwai K, Taniguchi A, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of 4\u00a0weeks\u2019 treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest. 2013;4(6):613\u20137.","journal-title":"J Diabetes Invest."},{"issue":"2","key":"298_CR15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499\u2013508.","journal-title":"J Clin Invest."},{"key":"298_CR16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-2840-12-70","volume":"12","author":"A Ring","year":"2013","unstructured":"Ring A, Brand T, Macha S, et al. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol. 2013;12:70.","journal-title":"Cardiovasc Diabetol."},{"issue":"11","key":"298_CR17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.5414\/CP201948","volume":"51","author":"S Macha","year":"2013","unstructured":"Macha S, Jungnik A, Hohl K, et al. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51(11):873\u20139.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"298_CR18","unstructured":"European Medicines Agency. Jardiance 10 and 25\u00a0mg film-coated tablets: summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002677\/human_med_001764.jsp&mid=WC0b01ac058001d124 . Accessed 17 June 2014."},{"issue":"4","key":"298_CR19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40262-013-0128-8","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53(4):295\u2013304.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"298_CR20","doi-asserted-by":"crossref","first-page":"A33","DOI":"10.1016\/j.clinthera.2012.12.002","volume":"35","author":"C Friedrich","year":"2013","unstructured":"Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35(1):A33\u201342.","journal-title":"Clin Ther."},{"issue":"10","key":"298_CR21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12325-012-0055-3","volume":"29","author":"T Brand","year":"2012","unstructured":"Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther. 2012;29(10):889\u201399.","journal-title":"Adv Ther."},{"issue":"2","key":"298_CR22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5414\/CP201794","volume":"51","author":"S Macha","year":"2013","unstructured":"Macha S, Dieterich S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51(2):132\u201340.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"298_CR23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7243\/2050-0866-1-14","volume":"1","author":"S Macha","year":"2012","unstructured":"Macha S, Mattheus M, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, cross-over study. Diabetes Res Clin Metab. 2012;1:14.","journal-title":"Diabetes Res Clin Metab."},{"issue":"3","key":"298_CR24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clinthera.2013.02.015","volume":"35","author":"S Macha","year":"2013","unstructured":"Macha S, Sennewald R, Rose P, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013;35(3):226\u201335.","journal-title":"Clin Ther."},{"issue":"4","key":"298_CR25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/dom.12028","volume":"15","author":"S Macha","year":"2013","unstructured":"Macha S, Rose P, Mattheus M, et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013;15(4):316\u201323.","journal-title":"Diabetes Obes Metab."},{"issue":"Suppl 1","key":"298_CR26","first-page":"A614","volume":"61","author":"T Giessmann","year":"2012","unstructured":"Giessmann T, Heise T, Macha S, et al. Lack of interaction between the sodium glucose cotransporter-2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with T2DM [abstract no. 2440-PO]. Diabetes. 2012;61(Suppl 1):A614\u20135.","journal-title":"Diabetes."},{"issue":"4","key":"298_CR27","first-page":"181","volume":"1","author":"S Macha","year":"2012","unstructured":"Macha S, Lang B, Pinnetti S, et al. Lack of pharmacokinetic interaction between the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin and simvastatin in healthy volunteers [abstract no. 1393585]. Clin Pharmacol Drug Dev. 2012;1(4):181.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"298_CR28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clinthera.2014.01.003","volume":"36","author":"S Macha","year":"2014","unstructured":"Macha S, Koenen R, Sennewald R, et al. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers. Clin Ther. 2014;36(2):280\u201390e.1.","journal-title":"Clin Ther"},{"issue":"5","key":"298_CR29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40261-013-0068-y","volume":"33","author":"S Macha","year":"2013","unstructured":"Macha S, Mattheus M, Pinnetti S, et al. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Clin Drug Investig. 2013;33(5):351\u20137.","journal-title":"Clin Drug Investig."},{"issue":"10","key":"298_CR30","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jcph.147","volume":"53","author":"MM Riggs","year":"2013","unstructured":"Riggs MM, Staab A, Seman L, et al. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. J Clin Pharmacol. 2013;53(10):1028\u201338.","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"298_CR31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.12182","volume":"16","author":"S Macha","year":"2014","unstructured":"Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16(3):215\u201322.","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"298_CR32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/dom.12183","volume":"16","author":"S Macha","year":"2014","unstructured":"Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab. 2014;16(2):118\u201323.","journal-title":"Diabetes Obes Metab."},{"key":"298_CR33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12325-014-0126-8","volume":"31","author":"T Kadowaki","year":"2014","unstructured":"Kadowaki T, Haneda M, Inagaki N, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther. 2014;31:621\u201338.","journal-title":"Adv Ther."},{"key":"298_CR34","unstructured":"Woerle HJ, Kadowaki T, Haneda M, et al. Safety and efficacy of empagliflozin monotherapy in a 52-week study in Japanese patients with type 2 diabetes mellitus [poster no. 930]. 49th Annual Meeting of the European Association for the Study of Diabetes, 23\u201327 Sep 2013, Barcelona."},{"key":"298_CR35","unstructured":"Tanaka Y, Araki E, Tanizawa Y, et al. Empagliflozin, a sodium glucose cotransporter inhibitor, as add-on therapy for 52\u00a0weeks in Japanese patients with type 2 diabetes mellitus [abstract]. 57th Annual Meeting of the Japan Diabetes Society, 22\u201324 May 2014, Osaka."},{"issue":"12","key":"298_CR36","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15(12):1154\u201360.","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"298_CR37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12081","volume":"15","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Seman L, Seewaldt-Becker E, et al. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721\u20138.","journal-title":"Diabetes Obes Metab."},{"key":"298_CR38","first-page":"A285","volume":"62","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Jelaska A, Wang F, et al. Empagliflozin as add-on to basal insulin for 78\u00a0weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM) [abstract no. 1102-P]. Diabetes. 2013;62:A285.","journal-title":"Diabetes."},{"issue":"3","key":"298_CR39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208\u201319.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"298_CR40","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","volume":"36","author":"H-U H\u00e4ring","year":"2013","unstructured":"H\u00e4ring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396\u2013404.","journal-title":"Diabetes Care."},{"issue":"2","key":"298_CR41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","volume":"16","author":"CS Kovacs","year":"2014","unstructured":"Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16(2):147\u201358.","journal-title":"Diabetes Obes Metab."},{"key":"298_CR42","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycaemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815\u201323.","journal-title":"Diabetes Care."},{"key":"298_CR43","author":"M Ridderstrale","year":"2014","unstructured":"Ridderstrale M, Andersen RK, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week, randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;. doi: 10.1016\/S2213-8587(14)70120-2 .","journal-title":"Lancet Diabetes Endocrinol."},{"key":"298_CR44","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"H-U H\u00e4ring","year":"2014","unstructured":"H\u00e4ring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650\u20139.","journal-title":"Diabetes Care."},{"issue":"12","key":"298_CR45","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36(12):4015\u201321.","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"298_CR46","first-page":"A273","volume":"63","author":"CS Kovacs","year":"2014","unstructured":"Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin (EMPA) for\u00a0\u226576\u00a0weeks as add-on to pioglitazone with or without metformin in patients with type 2 diabetes (T2DM) [abstract no.1055-P]. Diabetes. 2014;63(Suppl 1):A273.","journal-title":"Diabetes."},{"issue":"Suppl 1","key":"298_CR47","first-page":"A280","volume":"63","author":"H-U H\u00e4ring","year":"2014","unstructured":"H\u00e4ring H-U, Merker L, Christiansen AV, et al. Empagliflozin (EMPA) for\u00a0\u226576\u00a0weeks as add-on to metformin plus sulfonylurea (SU) in patients with type 2 diabetes (T2DM) [abstract no.1077-P]. Diabetes. 2014;63(Suppl 1):A280.","journal-title":"Diabetes."},{"issue":"Suppl 1","key":"298_CR48","first-page":"A69","volume":"63","author":"M Roden","year":"2014","unstructured":"Roden M, Weng J, Merker L, et al. Empagliflozin (EMPA) monotherapy for\u00a0\u226576\u00a0weeks in drug-naive patients with type 2 diabetes (T2DM) [abstract no.264-OR]. Diabetes. 2014;63(Suppl 1):A69.","journal-title":"Diabetes."},{"key":"298_CR49","doi-asserted-by":"crossref","unstructured":"Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2014. (in press).","DOI":"10.2337\/dc14-1096"},{"issue":"5","key":"298_CR50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369\u201384.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"298_CR51","unstructured":"Boehringer Ingelheim. Efficacy and safety of BI 10773 in combination with insulin in patients with type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT01011868]. US National Institutes of Health, ClinicalTrials.gov. 2014. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01011868?term=empagliflozin&rank=39 . Accessed 27 Aug 2014."},{"issue":"Suppl 1","key":"298_CR52","first-page":"65","volume":"31","author":"G Kim","year":"2014","unstructured":"Kim G, Gerich J, Salsali A, et al. Urinary tract infections and genital infections in patients with type 2 diabetes treated with empagliflozin: pooled data from four randomised, placebo-controlled phase III trials [abstract no. P125]. Diabet Med. 2014;31(Suppl 1):65.","journal-title":"Diabet Med"},{"key":"298_CR53","unstructured":"Boehringer Ingelheim International GmbH. Jardiance\u00ae (empagliflozin) tablets, for oral use: US prescribing information. 2014. http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing+Information\/PIs\/Jardiance\/jardiance.pdf . Accessed 15 Sept 2014."},{"issue":"2","key":"298_CR54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4158\/endp.19.2.a38267720403k242","volume":"19","author":"AJ Garber","year":"2013","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm. Endocr Pract. 2013;19(2):327\u201336.","journal-title":"Endocr Pract."},{"key":"298_CR55","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2009.12.004","volume":"123","author":"M Stolar","year":"2010","unstructured":"Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123:S3\u201311.","journal-title":"Am J Med."},{"issue":"2","key":"298_CR56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MAJ.0b013e3181ec04e9","volume":"341","author":"M Stolar","year":"2011","unstructured":"Stolar M. Addressing cardiovascular risk in patients with type 2 diabetes: focus on primary care. Am J Med Sci. 2011;341(2):132\u201340.","journal-title":"Am J Med Sci."},{"key":"298_CR57","unstructured":"National Institute for Health and Care Excellence. ESNM35 Type 2 diabetes: empagliflozin. 2014. http:\/\/www.nice.org.uk\/mpc\/evidencesummariesnewmedicines\/ESNM35.jsp . Accessed 20 June 2014."},{"key":"298_CR58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2840-13-102","volume":"13","author":"B Zinman","year":"2014","unstructured":"Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME\u2122). Cardiovasc Diabetol. 2014;13:102.","journal-title":"Cardiovasc Diabetol."},{"key":"298_CR59","first-page":"313","volume":"5","author":"Y Kim","year":"2012","unstructured":"Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes Targets Ther. 2012;5:313\u201327.","journal-title":"Diabetes Metab Syndr Obes Targets Ther."},{"issue":"4","key":"298_CR60","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2143\/ACB.3349","volume":"68","author":"J Cuypers","year":"2013","unstructured":"Cuypers J, Mathieu C, Benhalima K. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice. Acta Clin Belg. 2013;68(4):287\u201393.","journal-title":"Acta Clin Belg."},{"key":"298_CR61","first-page":"453","volume":"6","author":"RF Rosenwasser","year":"2013","unstructured":"Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes Targets Ther. 2013;6:453\u201367.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"9","key":"298_CR62","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/phar.1303","volume":"33","author":"SR Taylor","year":"2013","unstructured":"Taylor SR, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy. 2013;33(9):984\u201399.","journal-title":"Pharmacotherapy."},{"key":"298_CR63","unstructured":"European Medicines Agency. Summary of the risk management plan (RMP) for Jardiance (empagliflozin). 2014. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=\/pages\/medicines\/human\/medicines\/002677\/human_med_001764.jsp . Accessed 22 Aug 2014."}],"updated-by":[{"DOI":"10.1007\/s40265-014-0336-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T00:00:00Z","timestamp":1417046400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0298-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0298-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0298-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:39Z","timestamp":1559490099000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0298-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":63,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0298-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-014-0336-z","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}